Eventide Healthcare & Life Sciences Fund A (ETAHX)
49.26
-0.10
(-0.20%)
USD |
Nov 18 2026
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.54% | 1.521B | 0.00% | 87.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -139.83M | 4.96% |
Basic Info
| Investment Strategy | |
| The Fund seeks to provide long-term capital appreciation. The Fund will invest at least 80% of its net assets, plus borrowings for investment purposes, in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Small Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Eventide |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fund Flows
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of November 19, 2026.
Asset Allocation
As of June 30, 2026.
| Type | % Net |
|---|---|
| Cash | 4.01% |
| Stock | 92.18% |
| Bond | 3.24% |
| Convertible | 0.00% |
| Preferred | 1.28% |
| Other | -0.71% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Guardant Health, Inc. | 5.37% | 145.14 | 1.30% |
| Mirum Pharmaceuticals, Inc. | 3.47% | 92.49 | 0.59% |
|
USD Cash
|
3.42% | -- | -- |
| Kymera Therapeutics, Inc. | 3.22% | 121.13 | -0.32% |
| Abivax SA | 2.94% | 83.83 | 2.11% |
|
BeLite Bio Inc PIPE
|
2.83% | -- | -- |
| Trevi Therapeutics, Inc. | 2.77% | 13.51 | 0.00% |
| MBX Biosciences, Inc. | 2.70% | 53.42 | 0.60% |
| Vaxcyte, Inc. | 2.69% | 58.52 | -1.48% |
| Cytokinetics, Inc. | 2.69% | 51.32 | -0.64% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 0.25% |
| Actual Management Fee | 1.10% |
| Administration Fee | 63364.00 None |
| Maximum Front Load | 5.75% |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | 1.00% |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 1000.00 None |
| Minimum Subsequent Investment | 50.00 None |
TTM Distributions
| Type | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Qualified Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Normal
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Qualified
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
LT Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Ordinary Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Non-Qual
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ST Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Interest
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Tax-Exempt
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ROC
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Other
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Total
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
As of October 31, 2026.
Basic Info
| Investment Strategy | |
| The Fund seeks to provide long-term capital appreciation. The Fund will invest at least 80% of its net assets, plus borrowings for investment purposes, in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Small Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Eventide |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (11-18-26) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 89 |
| Stock | |
| Weighted Average PE Ratio | 35.90 |
| Weighted Average Price to Sales Ratio | 24.48 |
| Weighted Average Price to Book Ratio | 11.55 |
| Weighted Median ROE | -108.2% |
| Weighted Median ROA | -40.57% |
| Return on Investment (TTM) | -50.32% |
| Earning Yield | 0.0354 |
| LT Debt / Shareholders Equity | 1.032 |
| Number of Equity Holdings | 82 |
As of June 30, 2026
Growth Metrics
| EPS Growth (1Y) | 1.22% |
| EPS Growth (3Y) | 30.68% |
| EPS Growth (5Y) | 4.90% |
| Sales Growth (1Y) | 44.70% |
| Sales Growth (3Y) | 40.01% |
| Sales Growth (5Y) | 25.91% |
| Sales per Share Growth (1Y) | 767.3% |
| Sales per Share Growth (3Y) | 58.48% |
| Operating Cash Flow - Growth Rate (3Y) | 36.24% |
As of June 30, 2026
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:ETAHX", "name") |
| Broad Asset Class: =YCI("M:ETAHX", "broad_asset_class") |
| Broad Category: =YCI("M:ETAHX", "broad_category_group") |
| Prospectus Objective: =YCI("M:ETAHX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |